- Home
- MNDR vs IMRN Comparison
MNDR vs IMRN Comparison
Compare MNDR & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNDR
- IMRN
- Stock Information
- Founded
- MNDR 2016
- IMRN 1994
- Country
- MNDR Singapore
- IMRN Australia
- Employees
- MNDR N/A
- IMRN N/A
- Industry
- MNDR
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- MNDR
- IMRN Health Care
- Exchange
- MNDR Nasdaq
- IMRN Nasdaq
- Market Cap
- MNDR 9.3M
- IMRN 10.1M
- IPO Year
- MNDR 2024
- IMRN N/A
- Fundamental
- Price
- MNDR $1.43
- IMRN $1.72
- Analyst Decision
- MNDR
- IMRN Strong Buy
- Analyst Count
- MNDR 0
- IMRN 1
- Target Price
- MNDR N/A
- IMRN $5.00
- AVG Volume (30 Days)
- MNDR 51.8K
- IMRN 22.7K
- Earning Date
- MNDR 05-16-2025
- IMRN 05-06-2025
- Dividend Yield
- MNDR N/A
- IMRN N/A
- EPS Growth
- MNDR N/A
- IMRN N/A
- EPS
- MNDR N/A
- IMRN N/A
- Revenue
- MNDR $13,968,535.00
- IMRN $4,048,286.00
- Revenue This Year
- MNDR $188,831.77
- IMRN N/A
- Revenue Next Year
- MNDR $76.44
- IMRN N/A
- P/E Ratio
- MNDR N/A
- IMRN N/A
- Revenue Growth
- MNDR 77.38
- IMRN 82.90
- 52 Week Low
- MNDR $0.23
- IMRN $1.60
- 52 Week High
- MNDR $27.46
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- MNDR N/A
- IMRN 46.66
- Support Level
- MNDR N/A
- IMRN $1.64
- Resistance Level
- MNDR N/A
- IMRN $1.91
- Average True Range (ATR)
- MNDR 0.00
- IMRN 0.17
- MACD
- MNDR 0.00
- IMRN 0.00
- Stochastic Oscillator
- MNDR 0.00
- IMRN 31.00
About MNDR Mobile-health Network Solutions Class A Ordinary Shares
Mobile-health Network Solutions is a company engaged in providing telehealth solutions in terms of various matrices, such as the number of patient consultations per day and the ranking of its mobile application. It provides services on its MaNaDr platform, which is accessible via mobile application and website. The MaNaDr platform is a platform designed and created by doctors, for doctors and users, equipped with services like consultations with doctors, e-commerce pharma store, and others. The company's operating segments are Telemedicine and other services which is also its key revenue generating segment, and Sale of medicine and medical devices. Geographically, it derives revenue from Singapore.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.